Company

NeuExcell Therapeutics Inc.

NeuExcell Therapeutics develops gene therapies for neurodegenerative diseases and other neurological conditions.

About

Established in 2021, NeuExcell Therapeutics develops gene therapy drugs for neurological conditions and operates in Shanghai, Suzhou, and Philadelphia. It signed an agreement with Spark Therapeutics worth USD 190 million in 2021. In May 2023, it raised over USD 15 million in pre-Series A+ funding from China Science and Techinnovation Capital Management, HSCAPITAL, HX Pharma, Jiangxi Jimin Kexin Pharmaceutical Industry Investment, Jinkong Fund Management, Shanghai Zhangke Lingyi Investment Management Co., LTD, Suzhou Industrial Park Leader Venture Capital Co., Ltd., and Suzhou Trust.

2Funding rounds

8Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in